SEARCH

SEARCH BY CITATION

References

  • 1
    Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. HEPATOLOGY 1995; 21: 12381247.
  • 2
    International Working Party. Terminology of nodular hepatocellular lesions. HEPATOLOGY 1995; 22: 983989.
  • 3
    Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 11501153.
  • 4
    Kojiro M. “Nodule-in-nodule” appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004; 47: 179183.
  • 5
    Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208214.
  • 6
    Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl 2004; 10( Suppl 1): S3S8.
  • 7
    Ogata R, Majima Y, Tateishi Y, Kuromatsu R, Shimauchi Y, Torimyra T, et al. Bright loop appearance; a characteristic ultrasonography sign of early hepatocellular carcinoma. Oncol Rep 2000; 7: 12931298.
  • 8
    Roncalli M, Roz E, Coggi G, Di Rocco MG, Bossi P, Minola E, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. HEPATOLOGY 1999; 30: 11741178.
  • 9
    Iannaccone R, Laghi A, Catalano C, Rossi P, Mangiapane F, Murakami T, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 2005; 234: 460467.
  • 10
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421430.
  • 11
    Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. HEPATOLOGY 2005; 42: 2734.
  • 12
    Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005; 11: 281289.
  • 13
    Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. HEPATOLOGY 2004; 40: 13521360.
  • 14
    O'Malley M, Takayama Y, Sherman M. The fate of arterial enhancing nodules seen on triphasic ct scan in patients with chronic liver disease. Am J Gastro, in press.
  • 15
    Shimizu A, Ito K, Koike S, Fujita T, Shimizu K, Matsunaga N. Cirrhosis or chronic hepatitis: evaluation of small (<or=2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 2003; 226: 550555.
  • 16
    Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, et al. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005; 25: 7076.
  • 17
    An FQ, Matsuda M, Fujii H, Tang RF, Amemiya H, Dai YM, et al. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cells proliferation, expression and mutation of p53 and beta catenin. Int J Cancer 2001; 93: 468474.
  • 18
    Yano H, Nanashima A, Hidaka S, Haseba M, Tanaka K, Yamaguchi H, et al. Numerical aberrations of chroncsome 17 and the p53 locus in small hepatocellular carcinomas. Anticancer Res 2004; 24: 111115.
  • 19
    Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 55205525.
  • 20
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 8997.
  • 21
    Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 24182423.
  • 00
    LLovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel I, Schwartz M, et al. Comparison of gene transcriptional profiles in dysplastic nodules and earlu hepatocellular carcinoma in HCV cirrhosis: identification of molecular markers. J Hepatol 2005; 42( Suppl 2): 20.